Verrica Pharmaceuticals Inc. (VRCA), a dermatology therapeutics company, continues to expect genomic and T-cell (immune response) data from its Phase 2 clinical trial studying VP-315 for the treatment of basal cell carcinoma this quarter.
The company also intends to schedule an End-of-Phase 2 meeting with the FDA in the first half of 2025 to discuss the next steps for advancing the development of VP-315 for the treatment of basal cell carcinoma.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.